131 related articles for article (PubMed ID: 9885304)
1. Biopharmaceutical characterization of oral controlled/modified-release drug products. In vitro/in vivo correlation of roxatidine.
Frick A; Möller H; Wirbitzki E
Eur J Pharm Biopharm; 1998 Nov; 46(3):313-9. PubMed ID: 9885304
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of the H(2) blocker roxatidine acetate hydrochloride in pediatric patients, in comparison with healthy adult volunteers.
Nakamura H; Kawashima H; Azuma R; Sato I; Nagao K; Miyazawa K
Drug Metab Pharmacokinet; 2012; 27(4):422-9. PubMed ID: 22293541
[TBL] [Abstract][Full Text] [Related]
3. Gastroretentive mucoadhesive tablet of lafutidine for controlled release and enhanced bioavailability.
Patil S; Talele GS
Drug Deliv; 2015 May; 22(3):312-9. PubMed ID: 24471787
[TBL] [Abstract][Full Text] [Related]
4. [Plasma pharmacokinetics of roxatidine in the healthy man: correlation with gastric antisecretory effect].
Chen WW; Kolsky H; Lewin MJ; Bonfils S
Gastroenterol Clin Biol; 1990; 14(4):342-6. PubMed ID: 1972124
[TBL] [Abstract][Full Text] [Related]
5. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
6. Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin.
Frick A; Möller H; Wirbitzki E
Eur J Pharm Biopharm; 1998 Nov; 46(3):305-11. PubMed ID: 9885303
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of roxatidine acetate. Evidence from pharmacodynamic and clinical trials.
Merki HS; Bender W; Labs R
J Clin Gastroenterol; 1989; 11 Suppl 1():S20-3; discussion S24. PubMed ID: 2572621
[TBL] [Abstract][Full Text] [Related]
8. In-vitro and in-vivo characteristics of a modified-release double-pulse formulation for a water soluble drug.
Avramoff A; Domb AJ
Int J Clin Pharmacol Ther; 2010 Apr; 48(4):250-8. PubMed ID: 20353746
[TBL] [Abstract][Full Text] [Related]
9. Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms.
Lin Z; Zhou D; Hoag S; Qiu Y
AAPS J; 2016 Mar; 18(2):333-45. PubMed ID: 26769249
[TBL] [Abstract][Full Text] [Related]
10. FIP Guidelines for Dissolution Testing of Solid Oral Products.
Friedel HD; Brown CK; Barker AR; Buhse LF; Keitel S; Kraemer J; Morris JM; Reppas C; Sperry DC; Sakai-Kato K; Stickelmeyer MP; Shah VP
J Pharm Sci; 2018 Dec; 107(12):2995-3002. PubMed ID: 30148985
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of roxatidine in patients with renal insufficiency.
Gladziwa U; Wagner S; Sieberth HG; Klotz U
Br J Clin Pharmacol; 1995 Feb; 39(2):161-7. PubMed ID: 7742154
[TBL] [Abstract][Full Text] [Related]
12. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
13. The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men.
Lassman HB; Ho I; Puri SK; Sabo R; Scheffler MR
Drugs; 1988; 35 Suppl 3():53-64. PubMed ID: 2905250
[TBL] [Abstract][Full Text] [Related]
14. Penetration of roxatidine into the cerebrospinal fluid.
Tryba M; Kurz-Muller K
Scand J Gastroenterol Suppl; 1988; 146():153-8. PubMed ID: 2906459
[TBL] [Abstract][Full Text] [Related]
15. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs.
Pinheiro VA; Danopoulos P; Demirdjian L; Nogueira RJ; Dubois F
Int J Pharm Compd; 2013; 17(5):424-31. PubMed ID: 24459788
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
Wang R; Conner DP; Li BV
AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of roxatidine in healthy volunteers.
Collins JD; Pidgen AW
Drugs; 1988; 35 Suppl 3():41-7. PubMed ID: 2905248
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of roxatidine acetate in patients with chronic liver disease.
Tsutsumi M; Ueshima Y; Takase S
J Gastroenterol Hepatol; 2001 Aug; 16(8):910-5. PubMed ID: 11555106
[TBL] [Abstract][Full Text] [Related]
20. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
Heigoldt U; Sommer F; Daniels R; Wagner KG
Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
